Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.63 USD | +2.22% | -4.21% | +13.01% |
Feb. 27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 | |
Feb. 27 | Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01 | MT |
Evolution of the average Target Price on Myriad Genetics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Myriad Genetics, Inc.
BofA Securities | |
Goldman Sachs | |
Wells Fargo Securities | |
Wolfe Research | |
JPMorgan Chase | |
Morningstar | |
Jefferies & Co. | |
Stephens Inc. | |
Raymond James | |
SVB Securities LLC |
EPS Revisions
- Stock
- Equities
- Stock Myriad Genetics, Inc. - Nasdaq
- Consensus Myriad Genetics, Inc.